Literature DB >> 19665069

Prevalence of mutated TP53 on cDNA (but not on DNA template) in pleomorphic xanthoastrocytoma with positive TP53 immunohistochemistry.

Magdalena Zakrzewska1, Malgorzata Szybka, Wojciech Biernat, Tomasz Papierz, Piotr Rieske, Pawel P Liberski, Krzysztof Zakrzewski.   

Abstract

Pleomorphic xanthoastrocytoma (PXA) is a tumor of astrocytic lineage that may have anaplastic features; such a phenotype usually correlates with a less favorable outcome. The molecular profile of PXA differs from other astrocytic tumors, but the molecular mechanisms of its formation and progression are still undefined. We analyzed a loss of heterozygosity and mutations of the SMARCB1 (also known as SNF5 or INI1) and TP53 genes in four cases of PXA. In just one case a TP53 mutation (Cys238Tyr) was readily detectable at the mRNA level, but it was almost undetectable during DNA sequencing. This case was also the only one exhibiting anaplastic features and TP53 overexpression as defined by immunohistochemistry. This observation supports our earlier findings on discrepancies in TP53 status in glioblastomas. We suggest that the incidence of TP53 mutations in pleomorphic xanthoastrocytoma may be underestimated and that molecular approaches should be used for greater diagnostic precision.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19665069     DOI: 10.1016/j.cancergencyto.2009.04.023

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  4 in total

1.  Detection of P53 mutations in different cancer types is improved by cDNA sequencing.

Authors:  Sylwester Piaskowski; Izabela Zawlik; Malgorzata Szybka; Dominika Kulczycka-Wojdala; Ewelina Stoczynska-Fidelus; Michal Bienkowski; Tadeusz Robak; Renata Kusinska; Dorota Jesionek-Kupnicka; Radzislaw Kordek; Piotr Rieske; Pawel P Liberski
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

Review 2.  p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer.

Authors:  Kazuhiro Kobayashi; Hiroyuki Tomita; Masahito Shimizu; Takuji Tanaka; Natsuko Suzui; Tatsuhiko Miyazaki; Akira Hara
Journal:  Int J Mol Sci       Date:  2017-06-16       Impact factor: 5.923

3.  Demography, Pattern of Care, and Survival in Patients with Xanthoastrocytoma: A Systematic Review and Individual Patient Data Analysis of 325 Cases.

Authors:  Supriya Mallick; Prashanth Giridhar; Rony Benson; Wineeta Melgandi; Goura Kishor Rath
Journal:  J Neurosci Rural Pract       Date:  2019-10-07

4.  MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.

Authors:  Laura-Nanna Lohkamp; Maren Schinz; Claire Gehlhaar; Katrin Guse; Ulrich-Wilhelm Thomale; Peter Vajkoczy; Frank L Heppner; Arend Koch
Journal:  PLoS One       Date:  2016-06-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.